세계의 생체접합( Bioconjugation) 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 방법별, 생체분자 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Bioconjugation Market Growth & Trends:

The global bioconjugation market size is anticipated to reach USD 9.67 billion by 2030 and is projected to grow at a CAGR of 9.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The bioconjugation industry is driven by rising demand for targeted therapeutics and the growing adoption of antibody-drug conjugates (ADCs) in oncology and other treatments. Advancements in precision medicine and site-specific bioconjugation techniques are enhancing drug efficacy driving market expansion. Increasing biopharmaceutical R&D investments are accelerating innovation in biologics, protein conjugation, and nucleic acid-based therapies.

In addition, expanding applications in diagnostics, biomaterials, and drug delivery systems are also fueling growth, particularly with the rising adoption of biosensors and imaging agents. The surge in contract research (CROs) and contract manufacturing (CMOs) services for bioconjugation is further boosting market development. In addition, regulatory support, strategic industry collaborations, and technological advancements in click chemistry and linker technologies are key factors propelling the bioconjugation industry forward.

During the COVID-19 pandemic, the demand for bioconjugation technologies surged, particularly in vaccine development and rapid diagnostics. Bioconjugation played a crucial role in enhancing antigen stability and immune response, improving the efficacy of vaccines such as mRNA-based formulations. In addition, it was widely used in diagnostic assays, enabling faster and more accurate detection of the virus through biosensors and immunoassays. The urgent need for large-scale production led to increased outsourcing to CROs and CMOs, accelerating R&D and manufacturing. These factors underscored the critical role of bioconjugation in pandemic response and vaccine innovation.

Moreover, advancements in precision medicine and biologics are driving the demand for bioconjugation technologies, enabling targeted drug delivery and enhanced therapeutic efficacy. The rise of antibody-drug conjugates (ADCs), protein therapeutics, and gene therapies has increased the need for precise site-specific conjugation and improved linker chemistry. Bioconjugation also plays a key role in personalized treatments, ensuring higher specificity and reduced side effects. As biopharmaceutical R&D expands, the adoption of bioconjugation techniques in drug development, diagnostics, and biomaterials continues to grow, shaping the future of modern medicine.

However, the development of bioconjugated drugs, such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), involves high costs due to expensive raw materials, specialized equipment, and complex manufacturing processes. Producing stable and effective bioconjugates requires advanced linker technologies, site-specific conjugation methods, and stringent quality control, further driving up costs. In addition, high R&D expenses and long drug approval timelines pose significant financial risks for pharmaceutical and biotechnology companies. Regulatory hurdles, extensive clinical trials, and scalability challenges add to the burden, making bioconjugation drug development a capital-intensive and time-consuming process, limiting entry for smaller firms and startups.

Bioconjugation Market Report Highlights:

• The consumables segment led the market with the largest revenue share of 45.45% in 2024, due to the high demand for reagents, linkers, and labeling kits essential for bioconjugation processes. Increasing R&D activities and the growing adoption of antibody-drug conjugates (ADCs) further fueled segment growth. On the other hand, the services segment is expected to grow at the fastest CAGR over the forecast period.
• Based on technique, the chemical conjugation segment accounted for the largest market revenue share in 2024, due to its high efficiency, scalability, and widespread use in antibody-drug conjugates (ADCs), protein labeling, and nanoparticle functionalization. Its well-established protocols and compatibility with various biomolecules further drove its dominance. On the other hand, the click chemistry segment is expected to grow at the fastest CAGR over the forecast period.
• Based on biomolecule type, the antibodies segment accounted for the largest market revenue share in 2024, due to their crucial role in antibody-drug conjugates (ADCs), targeted therapeutics, and immunoassays. Their high specificity, stability, and widespread application in oncology, infectious diseases, and precision medicine further drive market dominance. On the other hand, the oligonucleotides segment is expected to grow at the fastest CAGR over the forecast period.
• Based on application, the therapeutics segment accounted for the largest revenue share in 2024, due to the rising adoption of antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and targeted drug delivery systems. Increasing demand for precision medicine, biologics, and cancer therapies further drives its market leadership. On the other hand, the diagnostics segment is expected to grow at the fastest CAGR over the forecast period.
• Based on end use, the pharmaceutical & biotechnological companies segment accounted for the largest market revenue share in 2024, due to increasing R&D investments, demand for targeted therapeutics, and the development of antibody-drug conjugates (ADCs) and biologics. Growing collaborations, outsourcing of bioconjugation services, and advancements in precision medicine further fueled market dominance. On the other hand, the CROs & CMOs segment is expected to grow at the fastest CAGR over the forecast period.
• The North America dominated the market with the largest revenue share of 43.75% in 2024, driven by strong biopharmaceutical R&D investments, high adoption of antibody-drug conjugates (ADCs), and advanced healthcare infrastructure. The presence of leading pharmaceutical & biotechnology companies, favorable regulatory support, and growing demand for precision medicine further fueled market growth. On the other hand, the Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Biomolecule Type
  • 1.2.3. Technique
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Bioconjugation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for targeted drug delivery
    • 3.2.1.2. Technological innovations in linker chemistry
    • 3.2.1.3. Growing applications in diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High development costs
    • 3.2.2.2. Short shelf life of bioconjugated products
    • 3.2.2.3. Alternative drug delivery technologies
• 3.3. Bioconjugation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Bioconjugation Market: Product & Services Estimates & Trend Analysis

• 4.1. Product & Services Segment Dashboard
• 4.2. Global Bioconjugation Market Product & Services Movement Analysis
• 4.3. Global Bioconjugation Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
• 4.4. Consumables
  • 4.4.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Reagents & Kits
    • 4.4.2.1. Reagents & kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2.2. Linker & Crosslinking Reagents & Kits
      • 4.4.2.2.1. Linker & crosslinking reagents & kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2.3. Labeling Reagents & Kits
      • 4.4.2.3.1. Labeling reagents & kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2.4. Modification Reagents & Kits
      • 4.4.2.4.1. Modification reagents & kits market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2.5. Other Reagents & Kits
      • 4.4.2.5.1. Other reagents & kits market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Labels
    • 4.4.3.1. Labels market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.2. Fluorescent Tags
      • 4.4.3.2.1. Fluorescent tags market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.3. Enzymes
      • 4.4.3.3.1. Enzymes market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.4. Haptens
      • 4.4.3.4.1. Haptens market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.5. Polymers
      • 4.4.3.5.1. Polymers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.6. Bead Coupling
      • 4.4.3.6.1. Bead coupling market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3.7. Other Labels
      • 4.4.3.7.1. Other labels market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Other Consumables
    • 4.4.4.1. Other consumables market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.2. Chromatography Systems
    • 4.5.2.1. Chromatography systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.3. Spectroscopy Instruments
    • 4.5.3.1. Spectroscopy instruments market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.4. Mass Spectrometers
    • 4.5.4.1. Mass spectrometers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.5. Flow Cytometers
    • 4.5.5.1. Flow cytometers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.6. Electrophoresis Equipment
    • 4.5.6.1. Electrophoresis equipment market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.7. Filtration Systems
    • 4.5.7.1. Filtration systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.8. Mixers & Shakers
    • 4.5.8.1. Mixers & shakers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.9. Incubators
    • 4.5.9.1. Incubators market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.10. Other Instruments
    • 4.5.10.1. Other instruments market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.2. Custom Synthesis & Conjugation Services
    • 4.6.2.1. Custom synthesis & conjugation services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.3. Analytical & Characterization Services
    • 4.6.3.1. Analytical & characterization services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.4. Scale-up & Manufacturing Services
    • 4.6.4.1. Scale-up & manufacturing services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.5. Other Services
    • 4.6.5.1. Other services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Bioconjugation Market: Biomolecule Type Estimates & Trend Analysis

• 5.1. Biomolecule Type Segment Dashboard
• 5.2. Global Bioconjugation Market Biomolecule Type Movement Analysis
• 5.3. Global Bioconjugation Market Size & Trend Analysis, by Biomolecule Type, 2018 to 2030 (USD Million)
• 5.4. Antibodies
  • 5.4.1. Antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Proteins
  • 5.5.1. Proteins market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Peptides
  • 5.6.1. Peptides market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Oligonucleotides
  • 5.7.1. Oligonucleotides market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Other Biomolecules
  • 5.8.1. Other biomolecules market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Bioconjugation Market: Technique Estimates & Trend Analysis

• 6.1. Technique Segment Dashboard
• 6.2. Global Bioconjugation Market Technique Movement Analysis
• 6.3. Global Bioconjugation Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
• 6.4. Chemical Conjugation
  • 6.4.1. Chemical conjugation market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Enzyme-Mediated Conjugation
  • 6.5.1. Enzyme-mediated conjugation market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Click Chemistry
  • 6.6.1. Click chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Photoreactive Crosslinking
  • 6.7.1. Photoreactive crosslinking market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Other Techniques
  • 6.8.1. Other techniques market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Bioconjugation Market: Application Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Bioconjugation Market Application Movement Analysis
• 7.3. Global Bioconjugation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Therapeutics
  • 7.4.1. Therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. Antibody-drug Conjugates
    • 7.4.2.1. Antibody-drug conjugates market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Protein-drug Conjugates
    • 7.4.3.1. Protein-drug conjugates market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Peptide-drug Conjugates
    • 7.4.4.1. Peptide-drug conjugates market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Other Therapeutic Applications
    • 7.4.5.1. Other therapeutic applications market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Research & Development
  • 7.5.1. Research & development market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Diagnostics
  • 7.6.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Bioconjugation Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Bioconjugation Market End Use Movement Analysis
• 8.3. Global Bioconjugation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Pharmaceutical & Biotechnology Companies
  • 8.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. CROs & CMOs
  • 8.5.1. CROs & CMOs market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Academic & Research Institutes
  • 8.6.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. Hospitals, Clinical, & Diagnostic Laboratories
  • 8.7.1. Hospitals, clinical, & diagnostic laboratories market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Bioconjugation Market: Regional Estimates & Trend Analysis by Product & Services, Biomolecule Type, Technique, Application, and End Use

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive scenario
    • 9.5.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Competitive scenario
    • 9.5.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.9. Denmark
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Regulatory framework
    • 9.5.9.3. Competitive scenario
    • 9.5.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Competitive scenario
    • 9.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key country dynamics
    • 9.8.5.2. Regulatory framework
    • 9.8.5.3. Competitive scenario
    • 9.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Danaher
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Thermo Fisher Scientific Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Lonza Group
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Merck KGaA (MilliporeSigma)
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Sartorius AG
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Abbvie, Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Bio-Rad Laboratories, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Agilent Technologies, Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Catalent, Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BD
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives